Bayer starts pivotal Parkinson’s cell therapy trial
Bayer’s much-anticipated stem cell therapy for Parkinson’s disease is gathering momentum, with dosing in phase 3 trials now underway. The first patient has already been treated with bemdaneprocel, a one-shot treatment designed to replace the dopamine-producing neurons that degenerate in Parkinson’s, which is being developed by Bayer’s BlueRock Therapeutics subsidiary. Meanwhile, Bayer is also making…
